Calcium metabolism in sarcoidosis and its clinical implications.

OBJECTIVE : To examine the clinical implications of disturbed calcium metabolism in sarcoidosis and how the pathophysiology affects management strategies. METHODS : The literature concerning calcium metabolism in sarcoidosis was reviewed. RESULTS : Dysregulated calcium metabolism is a well-recognized complication of sarcoidosis, resulting in hypercalcaemia (prevalence 5-10%), hypercalcuria (40-62%) and reduced bone density (40-55%). Extrarenal synthesis of calcitriol [1,25(OH)(2)D(3)] is central to the pathogenesis of abnormal calcium homeostasis, but alterations in parathyroid hormone (PTH) activity and the expression of PTH-related peptide have also been demonstrated. The immunosuppressive properties of calcitriol suggest that the raised levels seen in sarcoidosis could represent an adaptive response to the undefined antigen that causes sarcoidosis. CONCLUSIONS : The mechanisms of abnormal calcium metabolism in sarcoidosis need to be understood when treating hypercalcaemia, hypercalcuria and corticosteroid-induced osteoporosis. Studies are required to determine if the currently available therapies for osteoporosis are safe and effective in sarcoidosis.

[1]  G. Rizzato,et al.  Bone Mineral Content in Sarcoidosis , 1992 .

[2]  J. A. Janssen,et al.  [Hypercalcemia in sarcoidosis]. , 1989, Nederlands tijdschrift voor geneeskunde.

[3]  R. Crystal,et al.  Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. , 1985, The Journal of clinical investigation.

[4]  C. Cooper,et al.  Rheumatoid arthritis, corticosteroid therapy and hip fracture. , 1995, Annals of the rheumatic diseases.

[5]  F. Coe.  Nephrolithiasis: Pathogenesis and Treatment , 1988 .

[6]  T. Martin,et al.  Parathyroid-hormone-related protein in sarcoidosis. , 1998, The American journal of pathology.

[7]  R. Crystal,et al.  Corticosteroid therapy suppresses spontaneous interleukin 2 release and spontaneous proliferation of lung T lymphocytes of patients with active pulmonary sarcoidosis. , 1987, Journal of immunology.

[8]  C. Pak,et al.  Renal oxalate excretion following oral oxalate loads in patients with ileal disease and with renal and absorptive hypercalciurias. Effect of calcium and magnesium. , 1978, The American journal of medicine.

[9]  J. Müller‐Quernheim.  Sarcoidosis: immunopathogenetic concepts and their clinical application. , 1998, The European respiratory journal.

[10]  J. Adams.  Vitamin D metabolite-mediated hypercalcemia. , 1989, Endocrinology and metabolism clinics of North America.

[11]  S. Manolagas,et al.  Immunomodulating properties of 1,25-dihydroxyvitamin D3. , 1990, Kidney international. Supplement.

[12]  C. Pak.  Medical management of nephrolithiasis in Dallas: update 1987. , 1988, The Journal of urology.

[13]  L. Deftos.  Hypercalcemia: mechanisms, differential diagnosis, and remedies. , 1996, Postgraduate medicine.

[14]  S. Nagai,et al.  Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. , 1998, The European respiratory journal.

[15]  Hunninghake Gw.  Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis. , 1984 .

[16]  J. Adams,et al.  Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. , 1985, The Journal of clinical endocrinology and metabolism.

[17]  J. Eisman,et al.  Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. , 1993, The New England journal of medicine.

[18]  R. McFadden,et al.  Lymphocyte chemokinetic factors derived from human tonsils: modulation by 1,25-dihydroxyvitamin D3 (calcitriol). , 1991, American journal of respiratory cell and molecular biology.

[19]  J. Adams,et al.  Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. , 1983, The Journal of clinical investigation.

[20]  H. Koeffler,et al.  Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. , 1987, The Journal of clinical endocrinology and metabolism.

[21]  M. Fukase,et al.  Abnormal regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase activity by calcium and calcitonin in renal cortex from hypophosphatemic (Hyp) mice. , 1984, Endocrinology.

[22]  E. Lærum,et al.  Thiazide Prophylaxis of Urolithiasis , 1984 .

[23]  A. Trinchieri,et al.  The influence of diet on urinary risk factors for stones in healthy subjects and idiopathic renal calcium stone formers. , 1991, British journal of urology.

[24]  D. Fraser,et al.  Unique Biosynthesis by Kidney of a Biologically Active Vitamin D Metabolite , 1970, Nature.

[25]  B. Ettinger,et al.  Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. , 1988, The Journal of urology.

[26]  C. Cooper,et al.  A UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update , 1998, Journal of internal medicine.

[27]  M. Allon,et al.  The kidney in sarcoidosis. , 1993, Journal of the American Society of Nephrology : JASN.

[28]  H. DeLuca,et al.  Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. , 1979, The Journal of clinical investigation.

[29]  V. Pacovský,et al.  The tubular maximum for calcium reabsorption in patients with chronic active thoracic sarcoidosis. , 1990, The European respiratory journal.

[30]  H. E. Williams,et al.  Hyperoxaluria in patients with ileal resection: an abnormality in dietary oxalate absorption. , 1974, Gastroenterology.

[31]  E. Laerum,et al.  Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. , 2009, Acta medica Scandinavica.

[32]  J. Adams,et al.  Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. , 1990, The Journal of clinical endocrinology and metabolism.

[33]  J. Dequeker,et al.  Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. , 1986, Annals of the rheumatic diseases.

[34]  G. Rizzato.  Clinical impact of bone and calcium metabolism changes in sarcoidosis , 1998, Thorax.

[35]  R. Mason,et al.  Vitamin D conversion by sarcoid lymph node homogenate. , 1984, Annals of internal medicine.

[36]  E. Chen,et al.  A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. , 1987, Science.

[37]  V. Desmet,et al.  Renal involvement in sarcoidosis , 1970, Postgraduate medical journal.

[38]  J. Adams,et al.  Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis , 1985, The Journal of experimental medicine.

[39]  H. DeLuca,et al.  Absence of seasonal variation in serum concentrations of 1,25-dihydroxyvitamin D despite a rise in 25-hydroxyvitamin D in summer. , 1981, The Journal of clinical endocrinology and metabolism.

[40]  J. Strausz,et al.  Lung-restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. , 1992, The American review of respiratory disease.

[41]  J. Cadranel.  [The "vitamin D" endocrine and paracrine mediator in pulmonary granulomatosis]. , 1995, Revue des maladies respiratoires.

[42]  R. Crystal,et al.  Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. , 1981, The New England journal of medicine.

[43]  A. Norman,et al.  Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. , 1981, The New England journal of medicine.

[44]  T. Clemens,et al.  Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. , 1984, The Quarterly journal of medicine.

[45]  T. O'Leary,et al.  The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. , 1986, The New England journal of medicine.

[46]  R. Strieter,et al.  Th1 and Th2 responses regulate experimental lung granuloma development. , 1996, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[47]  Jacques P. Brown,et al.  Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .

[48]  R. Brown,et al.  Incomplete suppression of parathyroid hormone activity in sarcoidosis presenting with hypercalcaemia. , 1983, Postgraduate medical journal.

[49]  R. Crystal,et al.  Compartmentalized activation of the interleukin 2 gene by lung T lymphocytes in active pulmonary sarcoidosis. , 1986, Journal of immunology.

[50]  R. Crystal,et al.  Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. , 1983, The New England journal of medicine.

[51]  G. Macgregor.  1,25-DIHYDROXYCHOLECALCIFEROL IN PATHOGENESIS OF HYPERCALCÆMIC SARCOIDOSIS , 1979, The Lancet.

[52]  R. Robinson,et al.  Parathyroid adenoma with coexistent sarcoid granulomas. A hypercalcemic patient. , 1980, Archives of internal medicine.

[53]  Jacques P. Brown,et al.  Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. , 1997, The New England journal of medicine.

[54]  M. Twomey,et al.  Sarcoidosis with renal involvement. , 1978, Postgraduate medical journal.

[55]  D. Stevens,et al.  Ketoconazole blocks adrenal steroid synthesis. , 1982, Annals of internal medicine.

[56]  E. Rimm,et al.  A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. , 1993, The New England journal of medicine.

[57]  J. Muller-Quernheim.  Sarcoidosis: immunopathogenetic concepts and their clinical application , 1998 .

[58]  A. Tobler,et al.  1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[59]  R. Eastell,et al.  Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. , 1995, Annals of the rheumatic diseases.

[60]  P. Zabel,et al.  Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. , 1997, American journal of respiratory and critical care medicine.

[61]  H. Lithell,et al.  Dietary habits in renal stone patients compared with healthy subjects. , 1989, British Journal of Urology.

[62]  W. Bennett,et al.  Renal manifestations of sarcoidosis. , 1981, Archives of internal medicine.

[63]  A. Fournier,et al.  Effect of calcium restriction on renal excretion of oxalate and the probability of stones in the various pathophysiological groups with calcium stones. , 1983, The Journal of urology.

[64]  R. L. Taylor,et al.  Seasonal influence of sunlight on the hypercalcemia of sarcoidosis. , 1963, The American journal of medicine.

[65]  R. Lorenc,et al.  Evidence for extra-renal 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in pregnancy. , 1979, Science.

[66]  C. Pak.  Medical management of nephrolithiasis. , 1982, The Journal of urology.

[67]  T. Clemens,et al.  1, 25-DIHYDROXYCHOLECALCIFEROL IN THE PATHOGENESIS OF THE HYPERCALCÆMIA OF SARCOIDOSIS , 1979, The Lancet.

[68]  C. Eil,et al.  Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D. , 1986, The Journal of clinical endocrinology and metabolism.

[69]  J. Bilezikian.  Management of acute hypercalcemia. , 1992, The New England journal of medicine.

[70]  H. DeLuca,et al.  Bone mineral mobilization activity of 1,25-dihydroxycholecalciferol, a metabolite of vitamin D. , 1971, Archives of biochemistry and biophysics.

[71]  J. Adams,et al.  Potentiation of the macrophage 25-hydroxyvitamin D-1-hydroxylation reaction by human tuberculous pleural effusion fluid. , 1989, The Journal of clinical endocrinology and metabolism.

[72]  H. Beynon,et al.  Hypercalcaemia in sarcoidosis , 1999, The Lancet.

[73]  M. Hochberg,et al.  Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .

[74]  C. Eil,et al.  Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D and total serum calcium in hypercalcemic patients. , 1988, The Journal of clinical endocrinology and metabolism.

[75]  P. Rottoli,et al.  Prevention of Corticosteroid-Induced Osteoporosis with Alendronate in Sarcoid Patients , 1997, Calcified Tissue International.

[76]  A. Borsatti,et al.  Calcium oxalate nephrolithiasis: defective oxalate transport. , 1991, Kidney international.

[77]  G. Harrell,et al.  BLOOD CHEMICAL CHANGES IN BOECK'S SARCOID WITH PARTICULAR REFERENCE TO PROTEIN, CALCIUM AND PHOSPHATASE VALUES. , 1939, The Journal of clinical investigation.